Share on StockTwits

Myriad Genetics (NASDAQ:MYGN) Director John T. Henderson sold 5,000 shares of the stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $35.70, for a total transaction of $178,500.00. Following the completion of the sale, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $142,800. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

A number of research firms have recently commented on MYGN. Analysts at Macquarie reiterated a “neutral” rating on shares of Myriad Genetics in a research note on Thursday. They now have a $36.00 price target on the stock, down previously from $38.00. Separately, analysts at Credit Suisse reiterated a “hold” rating on shares of Myriad Genetics in a research note on Tuesday, May 13th. They now have a $40.00 price target on the stock, up previously from $38.00. Finally, analysts at Ned Davis Research upgraded shares of Myriad Genetics from a “neutral” rating to a “buy” rating in a research note on Monday, April 28th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $33.79.

Myriad Genetics (NASDAQ:MYGN) traded up 0.47% during mid-day trading on Friday, hitting $35.415. 410,339 shares of the company’s stock traded hands. Myriad Genetics has a 52-week low of $20.02 and a 52-week high of $42.50. The stock’s 50-day moving average is $36.98 and its 200-day moving average is $31.98. The company has a market cap of $2.650 billion and a P/E ratio of 14.95.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $0.48 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.45 by $0.03. The company had revenue of $182.92 million for the quarter, compared to the consensus estimate of $175.23 million. During the same quarter in the prior year, the company posted $0.46 earnings per share. The company’s quarterly revenue was up 16.9% on a year-over-year basis. On average, analysts predict that Myriad Genetics will post $2.39 earnings per share for the current fiscal year.

Myriad Genetics, Inc (NASDAQ:MYGN) is a molecular diagnostic company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.